Tran B, Voskoboynik M, Kim S-W, Lemech C, Carcereny E, Rha SY, Ahn M-J, Felip E, Lee KH, Álvarez EC, Yang JC-H, Ascierto PA, Pulla MP, Kondo S, Kuboki Y, Freeman D, Song X, Blando J, Eck S, Song FJ, Tang Z, Kuziora M, Gainer SD, Mitchell P, Asare J, Ayyoub A, Achour I, Subramaniam DS, Im S-A. Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy from a First-in-Human Study of Volrustomig, a Novel PD-1/CTLA-4 Bispecific Antibody. Clinical Cancer Research. 2026;32(14):10.1158/1078-0432.ccr-25-3447
To V, Thio N, Castle R, Macdonald S, Molden-Hauer T, Wells J, McMahon R, Bressel M, Tran B, Azad AA, Moon D, Appu S, Wong L-M, Murphy DG, Cuff K, Pryor D, Spain L, Au L, D’Souza C, Neeson PJ, Siva S. Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma. Nature Communications. 2026;:10.1038/s41467-026-74255-x
Panasci J, Park CL, Tran B, Siu LL. Advances in cancer immunotherapy: adoptive cell therapy and immune cell engagers in solid tumours. British Journal of Cancer. 2026;135(1):10.1038/s41416-026-03450-w
Pan HYC, Homewood D, Lucas H, Dittmer B, Teh J, O’Brien JS, Liu J, Tran B, Chee J, Churchill JA, Lawrentschuk N, Corcoran NM. The Australian Penile Cancer Clinical Registry: a comprehensive national approach to data collection. BJU International. 2026;138(Suppl 2):10.1111/bju.70188
Sherry AD, To V, D’souza C, Kiany S, Thio N, Liu S, Sun X, Castle B, Macdonald S, Choi H, Seo A, Hara K, Pryor D, Azad A, Tran B, Au L, Spain L, Ludmir EB, Jonasch E, Tannir NM, Msaouel P, Neeson P, Haymaker C, Tang C, Siva S. Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials. European Urology. 2026;90(1):10.1016/j.eururo.2026.03.024
Tran B, Dorff T, Richey M, Hankinson E, Olsen P, Karwa S, Sharpe J, Braunlin M, Kim C. Treatment Patterns and Survival Outcomes in a Real-World Cohort of Lutetium 177 Vipivotide Tetraxetan (LuPSMA)-Experienced Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC). Clinical Genitourinary Cancer. 2026;:10.1016/j.clgc.2026.102609
Xu YE, Hitchen N, Kamanat BV, O’Haire S, Harris W, Chan KH, Wilson M, Koyama T, Prasongsook N, Thambamroong T, Kho BP, Ting FIL, Vo TTP, Kim J, Voon P-J, Heong VYM, Ueno NT, Tran B, Tan DSW, Loong HHF. 177RO Regulatory approval delays for pembrolizumab and trastuzumab deruxtecan across the Asia-Pacific region. ESMO Open. 2026;11:10.1016/j.esmoop.2026.107978
Kashyap R, Buteau JP, Papa N, Ayati N, Eifer M, Betech-Antar V, Akhurst T, Alipour R, Kong G, Saghebi J, Ravi Kumar AS, Cardin A, Sandhu S, Tran B, Azad AA, Murphy DG, Hofman MS. Prognostic Value of Restaging [18F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [177Lu]Lu-PSMA-617 Therapy.Journal of Nuclear Medicine. 2026;:10.2967/jnumed.126.272531
Chow KVC, Conduit C, O’Haire S, Kuchel A, Wong S, Grimison P, Weickhardt A, Pranavan G, Lynam J, Bastick P, Goh J, Sengupta S, Smith A, Liow E, Campbell D, Wong M, Zlatic K, Gibbs P, Tran B, Gan CL. Extracranial, Extragonadal Germ Cell Tumors: A Multicenter Australian Case Series. Asia-Pacific Journal of Clinical Oncology. 2026;22(3):10.1111/ajco.70083
Dorff TB, Appleman LJ, Lin C-C, Lee JL, Tran B, Fischer S, Danila D, Gokani P, Gallent B, Pook DW. XALience: A phase 3, open-label, multicenter, randomized study of xaluritamig plus abiraterone vs investigator’s choice in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.Journal of Clinical Oncology. 2026;44(16_suppl):10.1200/jco.2026.44.16_suppl.tps5144
